Selected research
Industry Research
Indoleamine 2,3 Dioxygenase 1 Industry Research Report 2026
Market perspective
The global Indoleamine 2,3 Dioxygenase 1 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Indoleamine 2,3 Dioxygenase 1 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Indoleamine 2,3 Dioxygenase 1 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Indoleamine 2,3 Dioxygenase 1 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Indoleamine 2,3 Dioxygenase 1 include F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Company, Regen BioPharma Inc, Redx Pharma Plc, NewLink Genetics Corp, Netherlands Translational Research Center BV, Kyowa Hakko Kirin and IO Biotech ApS, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Indoleamine 2,3 Dioxygenase 1 market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Indoleamine 2,3 Dioxygenase 1 Market by Company
F. Hoffmann-La Roche Ltd
Pfizer Inc
Bristol-Myers Squibb Company
Regen BioPharma Inc
Redx Pharma Plc
NewLink Genetics Corp
Netherlands Translational Research Center BV
Kyowa Hakko Kirin
IO Biotech ApS
Incyte Corp
Globavir Biosciences Inc
Genentech Inc
Ensemble Therapeutics Corp
BirchBioMed Inc
Indoleamine 2,3 Dioxygenase 1 Segment by Type
BMS-986205
Dcellvax
F-001287
Galanal
Epacadostat
Others
Indoleamine 2,3 Dioxygenase 1 Segment by Application
Gastric Cancer
Aolpecia
Glioma
Cervical Cancer
Others
Indoleamine 2,3 Dioxygenase 1 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Indoleamine 2,3 Dioxygenase 1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Indoleamine 2,3 Dioxygenase 1 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Indoleamine 2,3 Dioxygenase 1.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Indoleamine 2,3 Dioxygenase 1 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Indoleamine 2,3 Dioxygenase 1 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Indoleamine 2,3 Dioxygenase 1 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- BMS-986205
- Dcellvax
- F-001287
- Galanal
- Epacadostat
- Others
Applications
- Gastric Cancer
- Aolpecia
- Glioma
- Cervical Cancer
- Others
Companies covered
- F. Hoffmann-La Roche Ltd
- Pfizer Inc
- Bristol-Myers Squibb Company
- Regen BioPharma Inc
- Redx Pharma Plc
- NewLink Genetics Corp
- Netherlands Translational Research Center BV
- Kyowa Hakko Kirin
- IO Biotech ApS
- Incyte Corp
- Globavir Biosciences Inc
- Genentech Inc
- Ensemble Therapeutics Corp
- BirchBioMed Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Indoleamine 2,3 Dioxygenase 1 Market Size (2021-2032)
- 2.2.2 Global Indoleamine 2,3 Dioxygenase 1 Sales (2021-2032)
- 2.2.3 Global Indoleamine 2,3 Dioxygenase 1 Market Average Price (2021-2032)
- 2.3 Indoleamine 2,3 Dioxygenase 1 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 BMS-986205
- 2.3.3 Dcellvax
- 2.3.4 F-001287
- 2.3.5 Galanal
- 2.3.6 Epacadostat
- 2.3.7 Others
- 2.4 Indoleamine 2,3 Dioxygenase 1 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Gastric Cancer
- 2.4.3 Aolpecia
- 2.4.4 Glioma
- 2.4.5 Cervical Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Indoleamine 2,3 Dioxygenase 1 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Indoleamine 2,3 Dioxygenase 1 Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Indoleamine 2,3 Dioxygenase 1 Revenue of Manufacturers (2021-2026)
- 3.4 Global Indoleamine 2,3 Dioxygenase 1 Average Price by Manufacturers (2021-2026)
- 3.5 Global Indoleamine 2,3 Dioxygenase 1 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Indoleamine 2,3 Dioxygenase 1, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Indoleamine 2,3 Dioxygenase 1, Product Type & Application
- 3.8 Global Manufacturers of Indoleamine 2,3 Dioxygenase 1, Established Date
- 3.9 Global Indoleamine 2,3 Dioxygenase 1 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 F. Hoffmann-La Roche Ltd
- 4.1.1 F. Hoffmann-La Roche Ltd Company Information
- 4.1.2 F. Hoffmann-La Roche Ltd Business Overview
- 4.1.3 F. Hoffmann-La Roche Ltd Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 F. Hoffmann-La Roche Ltd Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.1.5 F. Hoffmann-La Roche Ltd Recent Developments
- 4.2 Pfizer Inc
- 4.2.1 Pfizer Inc Company Information
- 4.2.2 Pfizer Inc Business Overview
- 4.2.3 Pfizer Inc Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.2.5 Pfizer Inc Recent Developments
- 4.3 Bristol-Myers Squibb Company
- 4.3.1 Bristol-Myers Squibb Company Company Information
- 4.3.2 Bristol-Myers Squibb Company Business Overview
- 4.3.3 Bristol-Myers Squibb Company Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bristol-Myers Squibb Company Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.3.5 Bristol-Myers Squibb Company Recent Developments
- 4.4 Regen BioPharma Inc
- 4.4.1 Regen BioPharma Inc Company Information
- 4.4.2 Regen BioPharma Inc Business Overview
- 4.4.3 Regen BioPharma Inc Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Regen BioPharma Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.4.5 Regen BioPharma Inc Recent Developments
- 4.5 Redx Pharma Plc
- 4.5.1 Redx Pharma Plc Company Information
- 4.5.2 Redx Pharma Plc Business Overview
- 4.5.3 Redx Pharma Plc Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Redx Pharma Plc Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.5.5 Redx Pharma Plc Recent Developments
- 4.6 NewLink Genetics Corp
- 4.6.1 NewLink Genetics Corp Company Information
- 4.6.2 NewLink Genetics Corp Business Overview
- 4.6.3 NewLink Genetics Corp Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 NewLink Genetics Corp Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.6.5 NewLink Genetics Corp Recent Developments
- 4.7 Netherlands Translational Research Center BV
- 4.7.1 Netherlands Translational Research Center BV Company Information
- 4.7.2 Netherlands Translational Research Center BV Business Overview
- 4.7.3 Netherlands Translational Research Center BV Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Netherlands Translational Research Center BV Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.7.5 Netherlands Translational Research Center BV Recent Developments
- 4.8 Kyowa Hakko Kirin
- 4.8.1 Kyowa Hakko Kirin Company Information
- 4.8.2 Kyowa Hakko Kirin Business Overview
- 4.8.3 Kyowa Hakko Kirin Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Kyowa Hakko Kirin Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.8.5 Kyowa Hakko Kirin Recent Developments
- 4.9 IO Biotech ApS
- 4.9.1 IO Biotech ApS Company Information
- 4.9.2 IO Biotech ApS Business Overview
- 4.9.3 IO Biotech ApS Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 IO Biotech ApS Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.9.5 IO Biotech ApS Recent Developments
- 4.10 Incyte Corp
- 4.10.1 Incyte Corp Company Information
- 4.10.2 Incyte Corp Business Overview
- 4.10.3 Incyte Corp Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Incyte Corp Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.10.5 Incyte Corp Recent Developments
- 4.11 Globavir Biosciences Inc
- 4.11.1 Globavir Biosciences Inc Company Information
- 4.11.2 Globavir Biosciences Inc Business Overview
- 4.11.3 Globavir Biosciences Inc Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Globavir Biosciences Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.11.5 Globavir Biosciences Inc Recent Developments
- 4.12 Genentech Inc
- 4.12.1 Genentech Inc Company Information
- 4.12.2 Genentech Inc Business Overview
- 4.12.3 Genentech Inc Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Genentech Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.12.5 Genentech Inc Recent Developments
- 4.13 Ensemble Therapeutics Corp
- 4.13.1 Ensemble Therapeutics Corp Company Information
- 4.13.2 Ensemble Therapeutics Corp Business Overview
- 4.13.3 Ensemble Therapeutics Corp Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Ensemble Therapeutics Corp Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.13.5 Ensemble Therapeutics Corp Recent Developments
- 4.14 BirchBioMed Inc
- 4.14.1 BirchBioMed Inc Company Information
- 4.14.2 BirchBioMed Inc Business Overview
- 4.14.3 BirchBioMed Inc Indoleamine 2,3 Dioxygenase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 BirchBioMed Inc Indoleamine 2,3 Dioxygenase 1 Product Portfolio
- 4.14.5 BirchBioMed Inc Recent Developments
5 Global Indoleamine 2,3 Dioxygenase 1 Market Scenario by Region
- 5.1 Global Indoleamine 2,3 Dioxygenase 1 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Indoleamine 2,3 Dioxygenase 1 Sales by Region: 2021-2032
- 5.2.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Region: 2021-2026
- 5.2.2 Global Indoleamine 2,3 Dioxygenase 1 Sales by Region: 2027-2032
- 5.3 Global Indoleamine 2,3 Dioxygenase 1 Revenue by Region: 2021-2032
- 5.3.1 Global Indoleamine 2,3 Dioxygenase 1 Revenue by Region: 2021-2026
- 5.3.2 Global Indoleamine 2,3 Dioxygenase 1 Revenue by Region: 2027-2032
- 5.4 North America Indoleamine 2,3 Dioxygenase 1 Market Facts & Figures by Country
- 5.4.1 North America Indoleamine 2,3 Dioxygenase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Indoleamine 2,3 Dioxygenase 1 Sales by Country (2021-2032)
- 5.4.3 North America Indoleamine 2,3 Dioxygenase 1 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Indoleamine 2,3 Dioxygenase 1 Market Facts & Figures by Country
- 5.5.1 Europe Indoleamine 2,3 Dioxygenase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Indoleamine 2,3 Dioxygenase 1 Sales by Country (2021-2032)
- 5.5.3 Europe Indoleamine 2,3 Dioxygenase 1 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Indoleamine 2,3 Dioxygenase 1 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Indoleamine 2,3 Dioxygenase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Indoleamine 2,3 Dioxygenase 1 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Indoleamine 2,3 Dioxygenase 1 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Indoleamine 2,3 Dioxygenase 1 Market Facts & Figures by Country
- 5.7.1 South America Indoleamine 2,3 Dioxygenase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Indoleamine 2,3 Dioxygenase 1 Sales by Country (2021-2032)
- 5.7.3 South America Indoleamine 2,3 Dioxygenase 1 Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Indoleamine 2,3 Dioxygenase 1 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Indoleamine 2,3 Dioxygenase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Indoleamine 2,3 Dioxygenase 1 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Indoleamine 2,3 Dioxygenase 1 Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Type (2021-2032)
- 6.1.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Indoleamine 2,3 Dioxygenase 1 Sales Market Share by Type (2021-2032)
- 6.2 Global Indoleamine 2,3 Dioxygenase 1 Revenue by Type (2021-2032)
- 6.2.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Indoleamine 2,3 Dioxygenase 1 Revenue Market Share by Type (2021-2032)
- 6.3 Global Indoleamine 2,3 Dioxygenase 1 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Application (2021-2032)
- 7.1.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Indoleamine 2,3 Dioxygenase 1 Sales Market Share by Application (2021-2032)
- 7.2 Global Indoleamine 2,3 Dioxygenase 1 Revenue by Application (2021-2032)
- 7.2.1 Global Indoleamine 2,3 Dioxygenase 1 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Indoleamine 2,3 Dioxygenase 1 Revenue Market Share by Application (2021-2032)
- 7.3 Global Indoleamine 2,3 Dioxygenase 1 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Indoleamine 2,3 Dioxygenase 1 Value Chain Analysis
- 8.1.1 Indoleamine 2,3 Dioxygenase 1 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Indoleamine 2,3 Dioxygenase 1 Production Mode & Process
- 8.2 Indoleamine 2,3 Dioxygenase 1 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Indoleamine 2,3 Dioxygenase 1 Distributors
- 8.2.3 Indoleamine 2,3 Dioxygenase 1 Customers
9 Global Indoleamine 2,3 Dioxygenase 1 Analyzing Market Dynamics
- 9.1 Indoleamine 2,3 Dioxygenase 1 Industry Trends
- 9.2 Indoleamine 2,3 Dioxygenase 1 Industry Drivers
- 9.3 Indoleamine 2,3 Dioxygenase 1 Industry Opportunities and Challenges
- 9.4 Indoleamine 2,3 Dioxygenase 1 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst